The Novartis Institute for Tropical Diseases (NITD) is hosting a global symposium in the Philippines, bringing world-renowned Dengue experts together to discuss critical issues facing Dengue treatment and prevention.
The four-day symposium will focus on best research practices and clinical management, as well as the growing global presence and unmet medical need to treat this neglected disease.
“Dengue is a devastating disease that is impacting the lives of millions globally, in the developing as well as the developed world” says Paul Herrling, Head of Corporate Research at Novartis and Chairman of the Novartis Institute for Tropical Diseases.
“Our long-term commitment to helping reduce this global disease burden is part of Novartis’ Corporate Citizenship efforts to improve access to medicines. By leveraging our experience, partnerships, and modern drug discovery tools, we hope to come closer to our goal of discovering effective treatments for tropical diseases.”
More than 50 million cases of Dengue and 500,000 Dengue-related hospitalisations occur each year in both developed and developing regions due to the under investment in research and development for effective tools to detect and treat the disease. Dengue is one of the most prevalent emerging diseases in humans with no preventative vaccines or antiviral cures available at present.